Fluorescein as a Brain Tumor Biomarker During Surgery
This study is looking at how well a dye called fluorescein helps surgeons see brain tumors during an operation. Doctors will compare fluorescein to another dye, ALA, and standard imaging (MRI scans) and tissue samples (histology). You could join if you are an adult (21 or older) with a brain tumor that doctors believe is a glioma (a type of brain cancer) and can be removed by surgery. The study aims to see how well fluorescein helps identify tumor tissue during surgery, with results expected in 24 months. The study is currently unclear on its recruitment status and plans to enroll 30 participants.
- Study design
- This study is interventional and will enroll 30 participants. You will be randomly assigned to receive either fluorescein alone or fluorescein plus ALA.
- What's involved
- You will participate in a single event, which is your brain surgery. Your pre- and post-operative MRI scans will be used, but these are part of your usual care.
- Compensation
- Not stated in the trial record.
- Follow-up
- There are no planned post-surgical follow-up visits specifically for this study. Your medical records will be used to monitor for any side effects.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- David W Roberts, MD · PRINCIPAL_INVESTIGATOR · Dartmouth-Hitchcock Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Fluorescein performance as an intraoperative biomarker for tumor tissue will be reported.24 months
The predictive performance of fluorescein fluorescence as an intraoperative imaging biomarker of tumor during surgery in patients with a clinical diagnosis of high grade glioma (HGG) and patients with a clinical diagnosis of low grade glioma (LGG) will be measured. Fluorescence will be measured both quantitatively via an intraoperative probe and visually by the neurosurgeon through the operating microscope. Endpoints will be assessed separately for HGG and LGG groups.